Home  >  News
Msc_Apr23 Advertisement
you can get e-magazine links on WhatsApp. Click here
  ABK Biomedical gets US FDA IDE approval for multi-centre pivotal study of Eye90 microspheres in hepatocellular carcinoma,   June 01, 2023
  Amgen to present new research on Otezla in psoriatic arthritis at EULAR 2023,   June 01, 2023
  AbbVie announces phase 2 study of upadacitinib alone or as a combo therapy meets primary and key secondary endpoints in patients with SLE,   June 01, 2023
  Pfizer reports positive marstacimab results from pivotal phase 3 haemophilia A and B trial,   June 01, 2023
  Sanofi announces positive phase 2 data of novel investigational anti-CD40L antibody frexalimab to treat relapsing multiple sclerosis,   June 01, 2023
  Genprex gets Safety Review Committee nod to advance to phase 2 expansion portion of Acclaim-1 trial of Reqorsa in combo with Tagrisso in advanced NSCLC,   May 31, 2023
  Hansa Biopharma begins patient dosing in GOOD-IDES-02 phase 3 trial of imlifidase to treat anti-GBM disease,   May 31, 2023
  Lotus Clinical Research expands partnership with Veeva to accelerate clinical trials,   May 31, 2023
  Amplia announces AMP945 combined with FOLFIRINOX enhances treatment effects in model of pancreatic cancer,   May 30, 2023
  LINK Medical, AlzeCure Pharma announce positive results from phase IIa study in neuropathic pain with the non-opioid ACD440,   May 30, 2023
  UK MHRA launches public consultation on ICH Good Clinical Practice Guideline which encourages innovation in clinical trials,   May 29, 2023
  DUO-E phase III trial shows Imfinzi plus Lynparza & Imfinzi alone both significantly improved PFS in advanced endometrial cancer when added to chemotherapy,   May 27, 2023
  Daiichi Sankyo to showcase latest research towards creating new standards of care for patients with cancer with data at ASCO & EHA,   May 27, 2023
  Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023,   May 27, 2023
  Milvexian granted US FDA fast track designation for all three indications under evaluation in phase 3 Librexia programme,   May 27, 2023
  Keytruda plus Lenvima demonstrates long-term, durable survival benefit versus sunitinib as first-line treatment for patients with advanced RCC,   May 27, 2023
  BioInvent, Transgene announce positive phase 1a data on oncolytic virus BT-001 in solid tumours,   May 26, 2023
  European study finds Abbott’s CardioMEMS HF System results in improved quality of life and 44% reduction in heart failure hospitalizations,   May 26, 2023
  AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023,   May 26, 2023
  Allgenesis announces positive data from the AG-73305 phase 2a trial to treat diabetic macular edema,   May 25, 2023

Copyright © 2016 Saffron Media Pvt. Ltd |